Market LIVE
Published markets; coverage varies by country
Product profile · United States

ABILIFY MAINTENA KIT

 ·  Patent Litigation & Settlement History ↓

IngredientARIPIPRAZOLE
Application typeNDA
Application202971
Product004
Dosage formFOR SUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
Strength400MG
Approval date2014-09-29
Marketing statusPrescription
Status event—
ApplicantOTSUKA PHARM CO LTD
Product source

Current GenericRadar decision

Year2023
SelectionDEEP_REVIEW
ReviewFINAL
Anchor typeDRUG_SUBSTANCE
Anchor date2023-08-06
Patent anchor2023-08-06
Exclusivity anchor2020-07-27
Protection date—
First Final ANDA—
Status event—

GNR judgment: DEEP_REVIEW. Reference year: 2023. Anchor type: DRUG_SUBSTANCE. Patent anchor: 2023-08-06. Exclusivity anchor: 2020-07-27. Anchor date: 2023-08-06. Patent tail: yes. Exclusivity tail: no. Review status: FINAL. Historical detailed rationale is retained in the evidence snapshot; this is a structured English summary, not a literal translation.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
109808032033-09-24U U-1632———
———
109808032033-09-24U U-543———
———
111545532033-09-24U U-814———
———
111545532033-09-24U U-1632———
———
111545532033-09-24U U-3245———
———
113445472033-09-24U U-1632———
———
113445472033-09-24U U-814———
———
113445472033-09-24U U-3245———
———
114000872033-09-24U U-814———
———
114000872033-09-24U U-3245———
———
114000872033-09-24U U-1632———
———
105250572034-03-08U U-2723———
———
105250572034-03-08U U-1632———
———
105250572034-03-08U U-543———
———
116483472034-04-06DP ————
———
126910562041-04-01U U-814———
———
126910562041-04-01U U-3245———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
I-746—2020-07-27Historical Orange Book exclusivity; scope and start date not independently established————Source

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.